The KN510713 Study in Combination With mFOLFIRINOX

This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).

Trial Details

NCT ID
NCT07114861
Phase
PHASE1 / PHASE2
Sponsor
New Cancer Cure-Bio Co.,Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX
  • Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX
Locations (sample)
  • Goyang-si, South Korea|37.65639,126.835

Key Eligibility Criteria

  • Adult male and female subjects aged 19 to 75 years at the time of providing written informed consent
  • Subjects with histologically or cytologically confirmed unresectable, locally advanced or metastatic PDAC who are scheduled to receive treatement w…
  • Subjects who have not received prior systemic chemotherapy for locally advanced or metastatic pancreatic cancer (Note: Prior neo-adjuvant or adjuva…
  • Subjects with at least one measurable lesion according to RECIST ver1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →